ADVL1412, A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
A study in children, adolescents, and young adults recurrent or refractory solid tumors using study drug nivolumab
Sponsor: CHOP
Enrolling: Male and Female Patients
IRB Number: AAAP1101
U.S. Govt. ID: NCT02304458
Contact: Alice Lee, MD: 212-305-2478 / al2041@cumc.columbia.edu
Additional Study Information: The purpose of this study is to learn what kind of side effects nivolumab as a single agent and nivolumab in combination with ipilimumab can cause and if these treatments are beneficial for solid tumors. Nivolumab (Dose Level 1) will be given as an intravenous infusion every 14 days of a 28 day cycle. If Dose Level 1 is not tolerable, then it will be decreased and a similar number of patients will be evaluated for tolerability at this dose. Once the recommended phase 2 dose of nivolumab is determined, the study will be expanded to see how well the drug works in specific disease types; neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Hodgkin lymphoma and non-Hodgkin lymphoma.
This study is closed
Investigator
Luca Szalontay, MD
Do You Qualify?
Have you or your child been diagnosed with a solid tumor? Yes No
Are you or your child between the ages of 12 months and 30 years of age? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Alice Lee, MD
al2041@cumc.columbia.edu
212-305-2478
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE